Compare AGNC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGNC | JAZZ |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 10.4B |
| IPO Year | N/A | 2007 |
| Metric | AGNC | JAZZ |
|---|---|---|
| Price | $10.54 | $185.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $11.03 | ★ $216.00 |
| AVG Volume (30 Days) | ★ 17.9M | 981.1K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 13.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | N/A | $6.17 |
| Revenue Next Year | $0.51 | $7.66 |
| P/E Ratio | $7.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $95.49 |
| 52 Week High | $12.19 | $198.00 |
| Indicator | AGNC | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 26.79 | 60.27 |
| Support Level | $10.16 | $159.78 |
| Resistance Level | $10.66 | $198.00 |
| Average True Range (ATR) | 0.23 | 6.03 |
| MACD | -0.08 | 0.40 |
| Stochastic Oscillator | 22.73 | 60.86 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.